Halozyme Therapeutics, Inc.

Historical 13F Holders

Symbol
HALO
CUSIP
40637H109
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 40637H109 since 12/18/2024, largest first.

Filer % of Class Filed
BlackRock, Inc. 13G/A 10.2% 7/17/2025
Event 6/30/2025
Vanguard Capital Management LLC 13G 5.2% 4/30/2026
Event 3/31/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (2)
State Street Corp 13G 4.9% 5/13/2025
Event 3/31/2025
Vanguard Group Inc 13G/A 0% 3/27/2026
Event 3/13/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 72 4.89 M $534 M
2026 Q2 694 135 M $9.83 B
2026 Q1 656 120 M $7.79 B
2025 Q4 639 125 M $8.40 B
2025 Q3 622 121 M $8.81 B
2025 Q2 571 119 M $6.13 B
2025 Q1 569 123 M $7.77 B
2024 Q4 530 124 M $5.87 B
2024 Q3 528 130 M $7.24 B
2024 Q2 474 127 M $6.63 B
2024 Q1 435 130 M $5.29 B
2023 Q4 433 131 M $4.83 B
2023 Q3 414 123 M $4.71 B
2023 Q2 389 123 M $4.45 B
2023 Q1 402 125 M $4.77 B
2022 Q4 441 135 M $7.69 B
2022 Q3 374 133 M $5.25 B
2022 Q2 380 128 M $5.65 B
2022 Q1 336 129 M $5.13 B
2021 Q4 344 130 M $5.22 B
2021 Q3 337 130 M $5.29 B
2021 Q2 332 130 M $5.89 B
2021 Q1 355 132 M $5.52 B
2020 Q4 364 137 M $5.84 B
2020 Q3 295 134 M $3.53 B
2020 Q2 291 136 M $3.64 B
2020 Q1 233 132 M $2.36 B
2019 Q4 252 130 M $2.30 B
2019 Q3 240 130 M $2.01 B
2019 Q2 234 124 M $2.13 B
2019 Q1 222 122 M $1.96 B
2018 Q4 211 123 M $1.79 B
2018 Q3 213 127 M $2.30 B
2018 Q2 208 124 M $2.09 B
2018 Q1 231 125 M $2.44 B
2017 Q4 220 123 M $2.48 B
2017 Q3 185 122 M $2.11 B
2017 Q2 186 122 M $1.56 B
2017 Q1 182 116 M $1.50 B
2016 Q4 191 111 M $1.10 B
2016 Q3 175 106 M $1.28 B
2016 Q2 177 105 M $909 M
2016 Q1 178 103 M $974 M
2015 Q4 185 101 M $1.75 B
2015 Q3 189 98.4 M $1.35 B
2015 Q2 174 97.6 M $2.20 B
2015 Q1 146 94.4 M $1.35 B
2014 Q4 149 92.1 M $890 M
2014 Q3 133 89.0 M $810 M
2014 Q2 143 87.2 M $862 M
2014 Q1 147 86.1 M $1.09 B